| 48.05 1.43 (3.07%) | 06-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 57.58 | 1-year : | 67.26 |
| Resists | First : | 49.3 | Second : | 57.58 |
| Pivot price | 40.51 |
|||
| Supports | First : | 41.37 |
Second : | 36.47 |
| MAs | MA(5) : | 43.82 |
MA(20) : | 40.33 |
| MA(100) : | 33.93 |
MA(250) : | 33.26 |
|
| MACD | MACD : | 1.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 89.3 |
D(3) : | 83.9 |
| RSI | RSI(14): 76 |
|||
| 52-week | High : | 49.3 | Low : | 25.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TGTX ] has closed It is unclear right now based on current values. 114.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 49.36 - 49.55 | 49.55 - 49.74 |
| Low: | 42.57 - 42.77 | 42.77 - 42.97 |
| Close: | 46.27 - 46.6 | 46.6 - 46.94 |
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Thu, 11 Jun 2026
TG Therapeutics posts late-stage trial win for Briumvi single infusion regimen - MSN
Thu, 11 Jun 2026
TG Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Thu, 11 Jun 2026
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Wed, 10 Jun 2026
TGTX Stock Surges As Briumvi Data Fuel Growth Story - StocksToTrade
Wed, 10 Jun 2026
TG Therapeutics Stock Is Surging Today: What's Driving The Action? - Benzinga
Tue, 09 Jun 2026
Why Is TG Therapeutics Stock Gaining Tuesday? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 153 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 70.2 (%) |
| Shares Short | 28,110 (K) |
| Shares Short P.Month | 28,730 (K) |
| EPS | 2.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.51 |
| Profit Margin | 65.9 % |
| Operating Margin | 16.9 % |
| Return on Assets (ttm) | 8.5 % |
| Return on Equity (ttm) | 112.5 % |
| Qtrly Rev. Growth | 69.5 % |
| Gross Profit (p.s.) | 3.79 |
| Sales Per Share | 4.57 |
| EBITDA (p.s.) | 0.97 |
| Qtrly Earnings Growth | 300 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | 16.8 |
| PEG Ratio | 1.6 |
| Price to Book value | 10.63 |
| Price to Sales | 10.5 |
| Price to Cash Flow | -527.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|